

PALATIN TECHNOLOGIES INC  
Form 8-K  
July 01, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported): June 27, 2008

**Palatin Technologies, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-15543**  
(Commission  
File Number)

**95-4078884**  
(IRS employer  
identification number)

**4C Cedar Brook Drive, Cranbury, NJ**  
(Address of principal executive offices)

**08512**  
(Zip Code)

Registrant's telephone number, including area code: **(609) 495-2200**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement.**

On June 27, 2008, we entered into an amendment (the Amendment ) to the Research Collaboration and License Agreement dated January 30, 2007 between AstraZeneca AB and us (the Agreement ). The Agreement was previously filed as Exhibit 10.2 of our quarterly report on Form 10-Q for the quarter ended December 31, 2006, filed with the SEC on February 8, 2007. Under the Amendment, we have granted AstraZeneca the right to license certain additional compounds, patents and patent applications for use in treatment of obesity, diabetes and related metabolic syndrome, and AstraZeneca has agreed to pay milestone payments thereon contingent upon development, regulatory and sales milestones, together with royalties on sale of approved products.

**Item 8.01 Other Events.**

On July 1, 2008, we issued a press release, attached hereto as Exhibit 99 and made part of this report, announcing the Amendment.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits:

99 Press Release dated July 1, 2008

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PALATIN TECHNOLOGIES, INC.

Date: July 1, 2008

By: /s/ Stephen T. Wills  
Stephen T. Wills, CPA, MST  
Executive Vice President -  
Operations and  
Chief Financial Officer

**EXHIBIT INDEX**

99 Press Release dated July 1, 2008